Literature DB >> 30488128

Differences in peri-operative serum inflammatory markers between normoponderal and obese patients undergoing large joint replacement for osteoarthritis-a descriptive study.

Mariana Cornelia Tilinca1, Ancuța Zazgyva2, Tudor Sorin Pop3.   

Abstract

PURPOSE: The occurrence, evolution and treatment outcome of osteoarthritis are influenced by a series of factors, including obesity. Assessing how chronic inflammation present in obesity changes the values of peri-operative biological tests could facilitate a clearer interpretation of laboratory examinations for the proper management of possible complications.
METHODS: This descriptive study compared biological and clinical factors during the peri-operative period in patients undergoing total hip/knee replacement, in order to identify the special characteristics of the inflammatory status in obese compared to normal weight patients. In the two groups (71 normoponderal, 74 obese), serum levels of fibrinogen, high-sensitivity C-reactive protein (hsCRP), tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) were determined 24 hours pre- and post-operatively.
RESULTS: Our results found significant post-operative increases in serum levels of IL-6 and hsCRP in both groups (p = 0.0001), with inter-group differences in pre-operative hsCRP (p = 0.02) and post-operative IL-6 levels (p = 0.013). Interestingly, TNF-alpha levels were much higher in the obese pre-operatively than post-operatively (p = 0.002) and higher than the normoponderals (p = 0.003), decreasing to levels similar to those of the normal weight patients on day two.
CONCLUSIONS: Because of its important clinical implications, an appropriate comprehension of the peri-operative changes in a patient's inflammatory status has the potential to influence therapeutic attitude. We failed to observe any significant post-operative differences in the mean values of the markers assessed, except those of IL-6, implying that serum levels of fibrinogen, hsCRP and TNF-alpha within 24 hours after large joint replacements are not influenced by the patient's ponderal status.

Entities:  

Keywords:  IL-6; Inflammatory markers; Joint replacement; Obesity; TNF-alpha; hsCRP

Mesh:

Substances:

Year:  2018        PMID: 30488128     DOI: 10.1007/s00264-018-4238-7

Source DB:  PubMed          Journal:  Int Orthop        ISSN: 0341-2695            Impact factor:   3.075


  23 in total

1.  Meta-analysis shows that obesity may be a significant risk factor for prosthetic joint infections.

Authors:  Zhongxi Ma; Fengjin Guo; Jun Qi; Wei Xiang; Jinming Zhang
Journal:  Int Orthop       Date:  2015-08-15       Impact factor: 3.075

2.  Not just loading and age: the dynamics of osteoarthritis, obesity and inflammation.

Authors:  Flavia M Cicuttini; Anita E Wluka
Journal:  Med J Aust       Date:  2016-02-01       Impact factor: 7.738

3.  Inflammation and post-operative recovery in patients undergoing total knee arthroplasty-secondary analysis of a randomized controlled trial.

Authors:  A Langkilde; T L Jakobsen; T Q Bandholm; J Eugen-Olsen; T Blauenfeldt; J Petersen; O Andersen
Journal:  Osteoarthritis Cartilage       Date:  2017-03-16       Impact factor: 6.576

4.  Relationship of serum IL-6, C-reactive protein, erythrocyte sedimentation rate, and knee skin temperature after total knee arthroplasty: a prospective study.

Authors:  Sittisak Honsawek; Benjamad Deepaisarnsakul; Aree Tanavalee; Manoon Sakdinakiattikoon; Srihatach Ngarmukos; Kanok Preativatanyou; Piyanuch Bumrungpanichthaworn
Journal:  Int Orthop       Date:  2010-02-21       Impact factor: 3.075

Review 5.  The pro- and anti-inflammatory properties of the cytokine interleukin-6.

Authors:  Jürgen Scheller; Athena Chalaris; Dirk Schmidt-Arras; Stefan Rose-John
Journal:  Biochim Biophys Acta       Date:  2011-02-04

6.  Association of obesity with inflammation and pain after total hip arthroplasty.

Authors:  Roja Motaghedi; James J Bae; Stavros G Memtsoudis; David H Kim; Jonathan C Beathe; Leonardo Paroli; Jacques T YaDeau; Michael A Gordon; Daniel B Maalouf; Yi Lin; Yan Ma; Susanna Cunningham-Rundles; Spencer S Liu
Journal:  Clin Orthop Relat Res       Date:  2014-05       Impact factor: 4.176

7.  Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome.

Authors:  D Aronson; P Bartha; O Zinder; A Kerner; W Markiewicz; O Avizohar; G J Brook; Y Levy
Journal:  Int J Obes Relat Metab Disord       Date:  2004-05

8.  Association Between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, and Hand Osteoarthritis: A Population-Based Cohort Study.

Authors:  Carlen Reyes; Kirsten M Leyland; George Peat; Cyrus Cooper; Nigel K Arden; Daniel Prieto-Alhambra
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

9.  Serum levels of proinflammatory cytokines in painful knee osteoarthritis and sensitization.

Authors:  Marta Imamura; Fernando Ezquerro; Fábio Marcon Alfieri; Lucy Vilas Boas; Tania Regina Tozetto-Mendoza; Janini Chen; Levent Özçakar; Lars Arendt-Nielsen; Linamara Rizzo Battistella
Journal:  Int J Inflam       Date:  2015-03-02

10.  Correlations between inflammatory cytokines, muscle damage markers and acute postoperative pain following primary total knee arthroplasty.

Authors:  Hai-Bo Si; Ti-Min Yang; Yi Zeng; Zong-Ke Zhou; Fu-Xing Pei; Yan-Rong Lu; Jing-Qiu Cheng; Bin Shen
Journal:  BMC Musculoskelet Disord       Date:  2017-06-17       Impact factor: 2.362

View more
  2 in total

1.  Normal trajectory of Interleukin-6 and C-reactive protein in the perioperative period of total knee arthroplasty under an enhanced recovery after surgery scenario.

Authors:  Ze Yu Huang; Qiang Huang; Li Ying Wang; Yi Ting Lei; Hong Xu; Bin Shen; Fu Xing Pei
Journal:  BMC Musculoskelet Disord       Date:  2020-04-21       Impact factor: 2.362

2.  Pre-emptive analgesia with methylprednisolone and gabapentin in total knee arthroplasty in the elderly.

Authors:  Henryk Liszka; Małgorzata Zając; Artur Gądek
Journal:  Sci Rep       Date:  2022-02-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.